Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Recruiting
Mirati Therapeutics Inc.
Phase 1/Phase 2
2019-01-15
This study will evaluate the safety, tolerability, drug levels, molecular effects, and
clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a
KRAS G12C mutation.
Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7
Recruiting
Mirati Therapeutics Inc.
Phase 2
2020-12-02
This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in
combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C
mutation and any PD-L1 TPS and who are candidates for first-line treatment.
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Recruiting
Mirati Therapeutics Inc.
Phase 3
2021-01-29
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849
(adagrasib) versus docetaxel in patients who have been previously treated for metastatic
NSCLC with a KRAS G12C mutation.
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Recruiting
Boehringer Ingelheim
Phase 1
2021-08-12
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical
activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced
solid tumors that have a KRAS G12C mutation.
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Recruiting
Mirati Therapeutics Inc.
Phase 1
2021-08-12
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical
activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced
solid tumors that have a KRAS G12C mutation.
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Recruiting
Mirati Therapeutics Inc.
Phase 1
2022-01-07
This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in
combination with palbociclib in patients with advanced solid tumor malignancies with KRAS
G12C mutation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
